Hook / Thesis
TG Therapeutics (TGTX) is showing the classic ingredients that attract takeover chatter: a rapidly growing commercial drug, improving top-line guidance and a share base with a meaningful short position. BRIUMVI's rollout has been the engine behind raised guidance and sequential acceleration; that combination has pushed the stock back toward its 52-week high and put buyers in control.
My stance: this is a tactical long where upside from either continued commercial momentum or an acquisitive bid can outpace headline risks. The trade is not without danger — valuation already reflects strong growth — so the plan is explicit: enter at current levels, use a firm stop below the prior consolidation, and take profits if upside validates a break to a substantially higher multiple or M&A premium.
What the company does and why the market should care
TG Therapeutics is a commercial-stage biopharma focused on B-cell malignancies and autoimmune disease. Its primary commercial driver today is BRIUMVI, an approved therapy for multiple sclerosis. The market cares because BRIUMVI is no longer an early launch product: it delivered $119.7 million in U.S. net sales in Q1 2025 and management raised full-year revenue guidance to $585 million on 08/04/2025 after reporting a 91% increase in Q2 2025 revenue. When a single product rapidly moves from promising to meaningful revenue, strategic options — including licensing deals, partnerships or outright acquisition — become realistic outcomes.
Supporting data - numbers that matter
- Market capitalization: roughly $8.31 billion.
- Trailing P/E: about 19.8; price-to-sales ~10.4; enterprise value roughly $8.57 billion.
- Free cash flow is small but positive: $17.385 million on the last reported basis.
- Commercial traction: BRIUMVI net sales $119.7 million in Q1 2025 and a full-year 2025 revenue guide of $585 million (announced 08/04/2025).
- Technicals: current price $55.42, above the 10- and 20-day SMAs (~$50.13 and ~$50.75) and RSI at ~59 with bullish MACD histogram — momentum is supportive.
- Short interest: recent settlement counts show ~29.3 million shares short with days-to-cover figures sometimes in double digits (recent snapshot 13.6 days), so there’s a non-trivial short base to squeeze if positive catalysts hit.
Valuation framing
On headline multiples the market is already assigning a premium: P/S near 10.4 and EV/EBITDA above 60 point to lofty expectations that future growth and margins will justify the current price. That premium is not irrational given the revenue guide of $585 million in 2025 and the potential for BRIUMVI to expand into additional dosing regimens and indications (management has flagged subcutaneous development and progressive MS exploration). Still, valuation is stretched relative to the company’s modest free cash flow and relatively small employee base (399 employees). In short: the story is priced for success, which raises the bar for operational execution or strategic outcomes such as M&A to justify further upside.
Catalysts to watch (2-5)
- Continued BRIUMVI sales cadence: further quarterly prints that top consensus and sustain the rise toward or beyond the $585M guidance mark will be the most direct fundamental catalyst.
- Regulatory/label expansion or new dosing data (subcutaneous formulation) that broadens prescribing use.
- Industry conferences and management commentary - e.g., investor events and fireside chats where updated enrollment, channel metrics or international plans are disclosed.
- Any M&A or partnership talk. Given the market cap and the strategic fit of BRIUMVI on larger immunology/rare disease platforms, even exploratory buyout interest would re-rate the stock higher quickly.
Trade plan (actionable)
Direction: Long.
Entry price: $55.42 (current market price).
Stop loss: $47.50 - a break and close below this level would signal a failure of the recent consolidation and reduce the odds of a sustained run.
Target: $75.00 - this reflects a mix of further commercial execution and either multiple expansion or a partial takeover premium. For traders who prefer layered exits, consider taking 50% of the position off at $68 and the remainder at $75.
Horizon: mid term (45 trading days) to long term (180 trading days). My base case is that material upside — whether from an earnings beat, new label news, or takeover chatter — will show up inside 45 trading days. If the story continues to develop (additional approvals, durable sales acceleration), hold into the 180 trading days window to capture larger re-ratings or transaction execution.
Why this specific setup?
Two dynamics make this trade attractive: commercial acceleration that validates the growth story and elevated short interest that can amplify moves if positive news appears. Technicals are aligned with a momentum-biased entry: price is above recent short-term moving averages and the MACD has turned bullish. The stop at $47.50 limits downside back toward the mid-March consolidation low area while leaving room for normal volatile swings in the story-driven biotech category.
Risks and counterarguments
- Valuation is rich. P/S ~10.4 and EV/EBITDA ~62.8 imply strong future growth and margin improvement. If growth slows or margins disappoint, the stock could re-rate lower quickly.
- Concentration risk. The commercial story is concentrated in BRIUMVI; setbacks on labeling, safety signals, or a competitor gaining ground could hit revenue sharply.
- Litigation and governance risk. A July 17, 2026 filing (Kuehn Law) indicates shareholder litigation scrutiny of management decisions; prolonged legal matters can distract management and weigh on sentiment.
- Low free cash flow and operational leverage. Free cash flow is small (~$17.4 million), meaning growth has been financed from other sources and the company could face liquidity pressure if sales growth stalls.
- Short-squeeze reversals can be volatile. Elevated short interest can fuel sharp rallies, but these are often followed by quick mean-reversions if the fundamental story does not support a sustained re-rating.
Counterargument: One credible opposing view is that the market already prices in BRIUMVI's best-case outcome. With a high P/S and EV/EBITDA, the stock could be vulnerable to a sanity check if upcoming quarters fail to show continued acceleration or if label expansion timelines slip. Investors who emphasize valuation discipline may prefer to wait for a pullback closer to the 50-day SMA (~$52.85) or stronger margin expansion evidence before initiating a position.
What would change my mind?
I would be less bullish if one or more of the following happens: (a) next two quarterly prints show materially slower BRIUMVI growth versus the $585M guidance, (b) a safety event or regulatory setback emerges, or (c) the company’s guidance is cut. Conversely, I would become more bullish if management demonstrates sustained quarter-over-quarter expansion, cash flow turns meaningfully positive, or if credible M&A interest becomes public.
Conclusion and final trade checklist
TG Therapeutics is a tradeable long idea because the combination of commercial momentum, elevated short interest and improving technicals creates asymmetric upside inside a clearly defined risk framework. Entry at $55.42 with a stop at $47.50 limits downside to levels where the launch narrative would likely be compromised; the $75 target prices in upside from either continued execution or transaction premium.
Before entering, confirm two items: (1) the next intra-quarter data or commentary does not materially undercut the BRIUMVI growth narrative, and (2) the technical structure holds support above $50 on pullbacks. Use position sizing discipline — this is a high-risk, event-driven idea.
Trade quick checklist: Enter $55.42 | Stop $47.50 | Target $75.00 | Horizon mid term (45 trading days) with optional hold to 180 trading days | Risk level: high.